Top Page
D.Western Therapeutics Institute
(Frankfurt:4576)
D.Western Therapeutics Institute (4576) vs. iShares MSCI Japan ETF (EWJ)
D.Western Therapeutics Institute Business Overview & Revenue Model
D.Western Therapeutics Institute Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 471.58M | 428.36M | 448.10M | 414.42M | 355.59M |
| Gross Profit | 424.74M | 391.70M | 420.53M | 394.32M | 338.57M |
| EBITDA | -1.23B | -775.59M | -390.75M | -110.03M | -240.64M |
| Net Income | -1.29B | -812.41M | -429.69M | -149.00M | -276.10M |
Balance Sheet | |||||
| Total Assets | 1.67B | 2.37B | 2.96B | 2.46B | 2.74B |
| Cash, Cash Equivalents and Short-Term Investments | 1.13B | 1.87B | 2.33B | 1.93B | 2.31B |
| Total Debt | 797.98M | 885.12M | 967.69M | 340.00M | 460.00M |
| Total Liabilities | 935.58M | 1.09B | 1.08B | 427.72M | 573.81M |
| Stockholders Equity | 733.87M | 1.28B | 1.86B | 2.01B | 2.16B |
Cash Flow | |||||
| Free Cash Flow | -1.31B | -601.76M | -364.58M | -179.21M | -221.41M |
| Operating Cash Flow | -1.30B | -586.82M | -354.77M | -176.31M | -216.28M |
| Investing Cash Flow | -10.01M | -15.25M | -139.89M | -111.15M | -13.46M |
| Financing Cash Flow | 567.63M | 134.47M | 867.30M | -104.46M | 1.00B |
D.Western Therapeutics Institute Technical Analysis
D.Western Therapeutics Institute Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ¥4.74B | 19.07 | ― | 18.71% | 33.40% | ||
65 Neutral | ¥354.70B | 11.38 | -2.99% | 2.49% | 11.76% | -10.21% | |
54 Neutral | ¥3.50B | ― | ― | 12.66% | 24.73% | ||
47 Neutral | ¥8.83B | ― | -148.36% | ― | 22.93% | 47.73% | |
42 Neutral | ¥5.35B | ― | -113.58% | ― | 4.59% | 9.71% | |
38 Underperform | ¥4.46B | ― | ― | 1056.04% | 21.63% | ||
28 Underperform | ¥8.64B | ― | ― | ― | -11.46% |
D.Western Therapeutics Institute Corporate Events
D. Western Therapeutics Institute has announced the development of ‘H-1129’ as a new pipeline candidate for treating ocular surface diseases related to immune disorders, such as keratoconjunctival diseases. This strategic move aims to leverage the company’s existing intellectual property and expertise in kinase inhibitors, following the discontinuation of its development as a glaucoma treatment. The company plans to initiate clinical trials in fiscal year 2026, with no immediate impact on the current earnings forecast, although future revisions may be announced if necessary.
D. Western Therapeutics Institute, Inc. has announced the launch of its glaucoma and ocular hypertension treatment, ‘GLA-ALPHA® Combination Ophthalmic Solution,’ in Thailand through its partner Kowa Co., Ltd. This marks the first international commercialization of the product, which combines ripasudil hydrochloride hydrate and brimonidine tartrate, offering a novel treatment option with a different action site compared to existing solutions. The launch is expected to enhance treatment adherence among patients requiring multiple medications, although the immediate financial impact on DWTI’s fiscal year is projected to be minimal. The company anticipates further overseas expansion following the steady growth of its products in Japan and Thailand.
D.Western Therapeutics Institute has announced a joint research agreement with Chordia Therapeutics to develop therapeutic agents for ophthalmic diseases using a compound from Chordia’s oncology pipeline. This collaboration leverages both companies’ expertise and resources, with Chordia providing research materials and D.Western conducting efficacy studies. While this partnership will not affect the current fiscal year’s earnings forecast, it is expected to expand D.Western’s ophthalmology pipeline in the medium to long term.
D.Western Therapeutics Institute announced that its partner, Kowa Co., Ltd., received marketing approval in Singapore for the GLA-ALPHA Combination Ophthalmic Solution, a novel treatment for glaucoma and ocular hypertension. This approval marks a significant step in DWTI’s international expansion strategy, as the product is already marketed in Japan and Thailand. While the approval does not immediately impact DWTI’s financial results, it is expected to enhance long-term earnings through royalties and improved market positioning.
D. Western Therapeutics Institute announced the completion of subject dosing in the global Phase III clinical trial of ‘K-321,’ an ophthalmic solution for treating Fuchs endothelial corneal dystrophy. This milestone marks a significant step in evaluating the efficacy and safety of K-321, which is administered post-Descemet’s membrane stripping surgery. The trial, conducted in multiple regions including the US and Europe, is now in the follow-up observation phase, with results expected by March 2026. The development of K-321 is crucial as it offers a potential new treatment option for a condition that currently relies heavily on corneal transplantation. Despite this progress, the company stated that there will be no change to the earnings forecast for the fiscal year ending December 2025.
D.Western Therapeutics Institute reported a decrease in net sales for the first quarter of 2025, with a 7.7% decline compared to the previous year. Despite the reduction in losses, the company still faces challenges with negative operating and ordinary profits, indicating ongoing financial difficulties.
D.Western Therapeutics Institute, in collaboration with RaQualia Pharma, has achieved positive results in their joint research aimed at developing new drug candidates for eye diseases. This research, which began in December 2022, confirmed favorable pharmacological effects in animal models and is expected to contribute to the medium-to-long-term expansion of DWTI’s ophthalmology pipeline, though it will not impact the current fiscal year’s earnings forecast.
D.Western Therapeutics Institute, Inc. has extended its joint research agreement with the University of Fukui to develop novel therapeutic and preventive drugs for cataracts. This collaboration aims to create an eye drop formulation as an alternative to cataract surgery, offering a broader range of treatment options and reducing the burden on patients. The extension of this agreement signifies the company’s commitment to advancing ophthalmological research, although it will not affect the earnings forecast for the fiscal year ending December 2025.
D.Western Therapeutics Institute’s subsidiary, Japan Innovative Therapeutics, Inc., has secured a patent in Macau for a diagnostic agent targeting retinopathy of prematurity and related conditions. This patent, which strengthens the company’s intellectual property portfolio, is expected to enhance corporate value over the medium to long term despite having no immediate impact on the fiscal earnings forecast.
D. Western Therapeutics Institute announced the presentation of late Phase II clinical trial results for their drug H-1337 at the ARVO 2025 conference, highlighting its significant intraocular pressure-lowering effects and tolerability for treating open-angle glaucoma and ocular hypertension. This presentation is expected to enhance the company’s international profile and support its licensing activities, although it will not affect the earnings forecast for the fiscal year ending December 2025.
D.Western Therapeutics Institute, Inc. has entered a joint research agreement with Mie University to develop new drugs for lifestyle-related diseases using their low-molecular-weight compounds. This collaboration will leverage zebrafish models for efficient drug screening, potentially enhancing the company’s capabilities and impact in the pharmaceutical industry, though it will not affect the current fiscal year’s earnings forecast.
D.Western Therapeutics Institute, Inc. has entered a joint research agreement with Professor Hitoshi Kasai of Tohoku University to develop next-generation drug formulations for eye diseases. This collaboration aims to address the increasing patient needs for effective treatments by enhancing drug efficacy and intraocular penetration, without impacting the company’s earnings forecast for the fiscal year ending December 2025.